HTA bodies are best known for their assessments of the value of new medicines, which can lead to countries choosing not to pay for approved products. Some of the bodies also play a role in assessing the value of new medical devices. The U.K. HTA body, for example, issued its first medical technology guidance in 2010.
The involvement of some HTAs in the assessments of medical devices led the European Commission to make medtech part of the regulation it proposed in 2018. By then, the device industry had already raised concerns about the application of a pharma-style HTA model to medtech.
